Titre : Anticorps de l'hépatite

Anticorps de l'hépatite : Questions médicales fréquentes

Termes MeSH sélectionnés :

Developing Countries
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite : Questions médicales les plus fréquentes", "headline": "Anticorps de l'hépatite : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Anticorps de l'hépatite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-27", "dateModified": "2025-04-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Anticorps antiviraux", "url": "https://questionsmedicales.fr/mesh/D000914", "about": { "@type": "MedicalCondition", "name": "Anticorps antiviraux", "code": { "@type": "MedicalCode", "code": "D000914", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite A", "alternateName": "Hepatitis A Antibodies", "url": "https://questionsmedicales.fr/mesh/D035922", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite A", "code": { "@type": "MedicalCode", "code": "D035922", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.251" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite B", "alternateName": "Hepatitis B Antibodies", "url": "https://questionsmedicales.fr/mesh/D006510", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite B", "code": { "@type": "MedicalCode", "code": "D006510", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.504" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite C", "alternateName": "Hepatitis C Antibodies", "url": "https://questionsmedicales.fr/mesh/D018937", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite C", "code": { "@type": "MedicalCode", "code": "D018937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.510" } } } ], "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite", "alternateName": "Hepatitis Antibodies", "code": { "@type": "MedicalCode", "code": "D006508", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mansun Law", "url": "https://questionsmedicales.fr/author/Mansun%20Law", "affiliation": { "@type": "Organization", "name": "Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California 92109, USA." } }, { "@type": "Person", "name": "Michiko Koga", "url": "https://questionsmedicales.fr/author/Michiko%20Koga", "affiliation": { "@type": "Organization", "name": "Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan." } }, { "@type": "Person", "name": "Makoto Saito", "url": "https://questionsmedicales.fr/author/Makoto%20Saito", "affiliation": { "@type": "Organization", "name": "Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan." } }, { "@type": "Person", "name": "Eisuke Adachi", "url": "https://questionsmedicales.fr/author/Eisuke%20Adachi", "affiliation": { "@type": "Organization", "name": "Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan." } }, { "@type": "Person", "name": "Amato Otani", "url": "https://questionsmedicales.fr/author/Amato%20Otani", "affiliation": { "@type": "Organization", "name": "Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Community-based interventions targeting multiple forms of malnutrition among adolescents in low-income and middle-income countries: protocol for a scoping review.", "datePublished": "2024-03-28", "url": "https://questionsmedicales.fr/article/38548368", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2023-078969" } }, { "@type": "ScholarlyArticle", "name": "Coverage and determinants of HIV testing and counseling services among mothers attending antenatal care in sub-Saharan African countries: a multilevel analysis.", "datePublished": "2024-03-27", "url": "https://questionsmedicales.fr/article/38539158", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-024-18373-5" } }, { "@type": "ScholarlyArticle", "name": "Regional disparities and risk factors of mortality among patients at high risk of sudden cardiac death in emerging countries: a nonrandomized controlled trial.", "datePublished": "2024-03-22", "url": "https://questionsmedicales.fr/article/38519982", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12916-024-03310-5" } }, { "@type": "ScholarlyArticle", "name": "Indirect Effects of the COVID-19 Pandemic on Routine Childhood Vaccination in Low-Income Countries: A Systematic Review to Set the Scope for Future Pandemics.", "datePublished": "2024-03-13", "url": "https://questionsmedicales.fr/article/38543624", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/microorganisms12030573" } }, { "@type": "ScholarlyArticle", "name": "Unintended pregnancy and contraception use among African women living with HIV: Baseline analysis of the multi-country US PEPFAR PROMOTE cohort.", "datePublished": "2024-03-11", "url": "https://questionsmedicales.fr/article/38466748", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0290285" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" }, { "@type": "ListItem", "position": 8, "name": "Anticorps antiviraux", "item": "https://questionsmedicales.fr/mesh/D000914" }, { "@type": "ListItem", "position": 9, "name": "Anticorps de l'hépatite", "item": "https://questionsmedicales.fr/mesh/D006508" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Anticorps de l'hépatite - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Anticorps de l'hépatite", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Anticorps de l'hépatite", "description": "Comment détecte-t-on les anticorps de l'hépatite ?\nQuels types d'anticorps sont testés ?\nQuand faut-il faire un test d'anticorps ?\nLes anticorps indiquent-ils une infection active ?\nPeut-on avoir des anticorps sans symptômes ?", "url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Anticorps de l'hépatite", "description": "Quels sont les symptômes de l'hépatite A ?\nL'hépatite B présente-t-elle des symptômes ?\nQuels symptômes sont associés à l'hépatite C ?\nLes symptômes de l'hépatite D sont-ils similaires ?\nQuels signes indiquent une hépatite E ?", "url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Anticorps de l'hépatite", "description": "Comment prévenir l'hépatite A ?\nQuelles mesures pour l'hépatite B ?\nL'hépatite C peut-elle être évitée ?\nY a-t-il un vaccin pour l'hépatite E ?\nComment réduire le risque d'hépatite D ?", "url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Anticorps de l'hépatite", "description": "Comment traite-t-on l'hépatite A ?\nQuels traitements existent pour l'hépatite B ?\nL'hépatite C peut-elle être guérie ?\nY a-t-il un vaccin pour l'hépatite B ?\nComment gérer l'hépatite D ?", "url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Anticorps de l'hépatite", "description": "Quelles complications peuvent survenir avec l'hépatite B ?\nL'hépatite C peut-elle causer des complications ?\nQuelles sont les complications de l'hépatite D ?\nL'hépatite A entraîne-t-elle des complications ?\nQuelles complications sont liées à l'hépatite E ?", "url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Anticorps de l'hépatite", "description": "Quels sont les facteurs de risque pour l'hépatite A ?\nQuels comportements augmentent le risque d'hépatite B ?\nQui est à risque pour l'hépatite C ?\nLes travailleurs de la santé sont-ils à risque d'hépatite ?\nLes personnes vivant avec le VIH sont-elles à risque d'hépatite ?", "url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Developing+Countries&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les anticorps de l'hépatite ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Par des tests sanguins spécifiques qui mesurent les anticorps présents." } }, { "@type": "Question", "name": "Quels types d'anticorps sont testés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les anticorps anti-HAV, anti-HBV, anti-HCV, anti-HEV, et anti-HDV." } }, { "@type": "Question", "name": "Quand faut-il faire un test d'anticorps ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Après une exposition suspectée ou en cas de symptômes d'hépatite." } }, { "@type": "Question", "name": "Les anticorps indiquent-ils une infection active ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, certains anticorps indiquent une infection passée ou une immunité." } }, { "@type": "Question", "name": "Peut-on avoir des anticorps sans symptômes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent être asymptomatiques tout en ayant des anticorps." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'hépatite A ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, fatigue, nausées, douleurs abdominales, jaunisse." } }, { "@type": "Question", "name": "L'hépatite B présente-t-elle des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être asymptomatique ou provoquer fatigue, douleurs articulaires, jaunisse." } }, { "@type": "Question", "name": "Quels symptômes sont associés à l'hépatite C ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, douleurs abdominales, jaunisse, mais souvent asymptomatique." } }, { "@type": "Question", "name": "Les symptômes de l'hépatite D sont-ils similaires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils ressemblent à ceux de l'hépatite B, avec des complications possibles." } }, { "@type": "Question", "name": "Quels signes indiquent une hépatite E ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, fatigue, nausées, et jaunisse, surtout dans les zones à risque." } }, { "@type": "Question", "name": "Comment prévenir l'hépatite A ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Vaccination, hygiène alimentaire, et lavage des mains sont essentiels." } }, { "@type": "Question", "name": "Quelles mesures pour l'hépatite B ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Vaccination, éviter le partage d'aiguilles et rapports protégés." } }, { "@type": "Question", "name": "L'hépatite C peut-elle être évitée ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le partage d'aiguilles et pratiquer des rapports protégés aide à prévenir." } }, { "@type": "Question", "name": "Y a-t-il un vaccin pour l'hépatite E ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccin commercialisé pour l'hépatite E." } }, { "@type": "Question", "name": "Comment réduire le risque d'hépatite D ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Prévenir l'hépatite B par vaccination réduit le risque d'hépatite D." } }, { "@type": "Question", "name": "Comment traite-t-on l'hépatite A ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de traitement spécifique, repos et hydratation sont recommandés." } }, { "@type": "Question", "name": "Quels traitements existent pour l'hépatite B ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Antiviraux comme la lamivudine ou l'interféron peuvent être prescrits." } }, { "@type": "Question", "name": "L'hépatite C peut-elle être guérie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avec des antiviraux à action directe, la guérison est possible." } }, { "@type": "Question", "name": "Y a-t-il un vaccin pour l'hépatite B ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un vaccin efficace est disponible pour prévenir l'hépatite B." } }, { "@type": "Question", "name": "Comment gérer l'hépatite D ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement de l'hépatite B est essentiel, car l'hépatite D dépend de celle-ci." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'hépatite B ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Cirrhose, cancer du foie, et insuffisance hépatique sont des complications possibles." } }, { "@type": "Question", "name": "L'hépatite C peut-elle causer des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut mener à la cirrhose et au cancer du foie sur le long terme." } }, { "@type": "Question", "name": "Quelles sont les complications de l'hépatite D ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut aggraver l'hépatite B, entraînant des complications hépatiques sévères." } }, { "@type": "Question", "name": "L'hépatite A entraîne-t-elle des complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Rarement, mais des cas graves peuvent survenir, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Quelles complications sont liées à l'hépatite E ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Peuvent inclure des cas graves chez les femmes enceintes, comme l'insuffisance hépatique." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'hépatite A ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Voyages dans des zones à risque, consommation d'eau contaminée, et aliments crus." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque d'hépatite B ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Partage d'aiguilles, rapports non protégés, et transfusions sanguines non testées." } }, { "@type": "Question", "name": "Qui est à risque pour l'hépatite C ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les consommateurs de drogues injectables et les personnes ayant des rapports à risque." } }, { "@type": "Question", "name": "Les travailleurs de la santé sont-ils à risque d'hépatite ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont exposés à des fluides corporels et doivent suivre des protocoles de sécurité." } }, { "@type": "Question", "name": "Les personnes vivant avec le VIH sont-elles à risque d'hépatite ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles ont un risque accru d'infections par les virus de l'hépatite." } } ] } ] }

Sources (10000 au total)

Community-based interventions targeting multiple forms of malnutrition among adolescents in low-income and middle-income countries: protocol for a scoping review.

Adolescent malnutrition is a significant public health challenge in low-income and middle-income countries (LMICs), with long-term consequences for health and development. Community-based intervention... A comprehensive search strategy will be implemented in multiple databases including MEDLINE (through PubMed), Embase, CENTRAL (through Cochrane Library) and grey literature, covering the period from 1... The scope of this scoping review is restricted to publicly accessible databases that do not require prior ethical approval for access. The findings of this review will be shared through publications i... The final protocol was registered prospectively with the Open Science Framework on 19 July 2023 (https://osf.io/t2d78)....

Coverage and determinants of HIV testing and counseling services among mothers attending antenatal care in sub-Saharan African countries: a multilevel analysis.

HIV/AIDS is one of the top global public health threats that causes significant cases, deaths, and socioeconomic impact. Even though both HIV testing and counseling are identified as essential HIV int... This study was conducted on large national-representative data from the Demographic Health Survey (DHS) using multilevel analysis. Data extraction, cleaning, coding, and statistical analysis were perf... A total of 83,584 women attending antenatal care were included in this study. HIV testing and counseling coverage in sub-Saharan Africa was found to be 62.87% with a 95% CI of 62.54-63.19%. The HIV te... This study revealed that HIV testing and counseling coverage was 62.87% in sub-Saharan Africa. Factors affecting the HIV testing and counseling coverage were age, education, frequency of antenatal car...

Regional disparities and risk factors of mortality among patients at high risk of sudden cardiac death in emerging countries: a nonrandomized controlled trial.

Comprehensive data on patients at high risk of sudden cardiac death (SCD) in emerging countries are lacking. The aim was to deepen our understanding of the SCD phenotype and identify risk factors for ... Patients who met the class I indication for implantable cardioverter-defibrillator (ICD) implantation according to guideline recommendations in 17 countries and regions underrepresented in previous tr... We enrolled 4222 patients, and 3889 patients were included in the analysis. The mean follow-up period was 21.6 ± 10.2 months. There were 433 (11.1%) instances of all-cause mortality and 117 (3.0%) cas... There was significant heterogeneity among patients with high SCD risk in emerging countries. The influences of geographic regions on patient characteristics and outcomes were significant. Improvement ... ClinicalTrials.gov, NCT02099721....

Unintended pregnancy and contraception use among African women living with HIV: Baseline analysis of the multi-country US PEPFAR PROMOTE cohort.

About 90% of unintended pregnancies are attributed to non-use of effective contraception-tubal ligation, or reversible effective contraception (REC) including injectables, oral pills, intra-uterine co... We conducted cross-sectional analyses of the US-PEPFAR PROMOTE study WLHIV on ART at enrollment. Separate outcome (REC and LARC) modified-Poisson regression models were used to estimate prevalence ris... Of 1,987 enrolled WLHIV, 990 (49.8%) reported their last/current pregnancy was unintended; 1,027/1,254 (81.9%) non-pregnant women with a potential to become pregnant reported current use of effective ... Unintended pregnancy was common while use of effective contraception methods particularly LARCs was low among these African WLHIV. HIV viral load, education, sexual-activity, fertility desires, and ec...

Comparison of Brazilian High- and Maximum-Containment Laboratories Biosafety and Biosecurity Regulations to Legal Frameworks in the United States and Other Countries: Gaps and Opportunities.

Although the United States and other countries have implemented comprehensive legislation, regulations, and policies to support biosafety and biosecurity of high- and maximum-containment laboratories,... To evaluate the Brazilian approach to ensuring nationwide biosafety and biosecurity oversight and governance of high- and maximum-containment laboratories.... A systematic gap analysis was conducted to compare Brazilian biosafety and biosecurity legislation, regulations, and policies with their international counterparts, with a particular focus on the over... We found that Brazilian biosafety and biosecurity legislation, regulations, and policies have relevant gaps. Governance and regulatory oversight of Brazil's high- and maximum-containment laboratories ... The Brazilian government has an opportunity to revise and improve upon a national set of legislation, regulations, and policies for its high- and maximum-containment laboratories, taking advantage of ...

Cigarette excise tax structure and cigarette prices in nine sub-Saharan African countries: evidence from the Global Adult Tobacco Survey.

Economic theory predicts that the excise tax structure influences the distribution of cigarette prices. Evidence shows that uniform specific excise tax structures exhibit the least price variability r... To examine the distribution of cigarette prices under different tax structures in nine African countries and to critically evaluate the effectiveness of African regional tax directives in promoting pu... Data from the Global Adult Tobacco Survey, conducted in eight African countries during 2012-2018, and data from the 2017 Gambia Tobacco Survey were used to construct survey-derived cigarette prices. T... The least price variability is found in countries with a uniform specific tax, or a mixed system with a minimum specific floor. Cigarette price variability is largest in countries with uniform ad valo... Regional tax directives that require the adoption of uniform specific excise taxes, or high minimum specific floors, could be an efficient way to get multiple African countries to adopt a tax structur...

Acute care pathway assessed through performance indicators during the COVID-19 pandemic in OECD countries (2020-2021): a scoping review.

The COVID-19 pandemic severely impacted care for non-COVID patients. Performance indicators to monitor acute care, timely reported and internationally accepted, lacked during the pandemic in OECD coun... Scoping review. Search in Embase and MEDLINE (07-07-2022). Acute care performance indicators and indicators related to acute general surgery were collected and collated following a care pathway approa... A total of 152 studies were included. 2354 indicators regarding general acute care and 301 indicators related to acute general surgery were included. Indicators focusing on pre-hospital services repor... This review signals relevant disruptions across the acute care pathway. A subset of general surgery performance indicators showed stability in most of the phases of the care pathway. These results hig...